Journal article
Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate
Abstract
OBJECTIVES: To compare health-related quality of life (HRQoL), as measured by health utility, in patients with rheumatoid arthritis (RA) treated with adalimumab (a human anti-tumour necrosis factor (anti-TNF) monoclonal antibody) plus methotrexate or placebo plus methotrexate.
METHODS: HRQoL data were obtained in two randomized, double-blind, placebo-controlled, multidose clinical trials conducted in the United States and Canada. The Health …
Authors
Torrance GW; Tugwell P; Amorosi S; Chartash E; Sengupta N
Journal
Rheumatology, Vol. 43, No. 6, pp. 712–718
Publisher
Oxford University Press (OUP)
Publication Date
June 1, 2004
DOI
10.1093/rheumatology/keh153
ISSN
1462-0324